ABP 980 regulatory update

Amgen submitted a regulatory application in the EU for ABP 980, a biosimilar of Herceptin trastuzumab from Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland). Amgen is seeking approval of ABP 980 for al...